Drug Profile
KN 020
Alternative Names: KN-020Latest Information Update: 28 Jul 2021
Price :
$50
*
At a glance
- Originator Alphamab
- Developer Jiangsu Alphamab Biopharmaceuticals
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Haematological disorders
Most Recent Events
- 28 Jul 2021 No recent reports of development identified for research development in Haematological-disorders in China
- 12 Jul 2019 KN 020 is still in early research for Haematological disorders in China (Alphamab pipeline, July 2019)
- 07 May 2015 Early research in Haematological disorders in China (unspecified route) (Alphamab pipeline, May 2015)